MARKET

ELUT

ELUT

Elutia Inc.
NASDAQ
1.170
+0.080
+7.34%
Opening 12:07 03/12 EDT
OPEN
1.090
PREV CLOSE
1.090
HIGH
1.210
LOW
1.090
VOLUME
181.23K
TURNOVER
--
52 WEEK HIGH
3.460
52 WEEK LOW
0.5000
MARKET CAP
50.08M
P/E (TTM)
-1.7138
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Stryker (SYK) and Elutia (ELUT)
TipRanks · 6h ago
Elutia outlines launch timeline for NXT-41x in $1.5B breast reconstruction market while strengthening leadership team
Seeking Alpha · 19h ago
Elutia Q4 revenue rises on higher cardiovascular product sales
Reuters · 23h ago
Elutia GAAP EPS of $1.48 beats by $1.62, revenue of $3.3M in-line
Seeking Alpha · 23h ago
*Elutia Sees FDA Clearance in 2H of 2026 and Full NXT-41x Clearance in 1H of 2027
Dow Jones · 23h ago
*Elutia 4Q Sales $3.27M >ELUT
Dow Jones · 23h ago
*Elutia 4Q EPS $1.48 >ELUT
Dow Jones · 23h ago
*Elutia: Base Biologic Matrix NXT-41 Submitted to FDA
Dow Jones · 23h ago
More
About ELUT
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.

Webull offers Elutia Inc stock information, including NASDAQ: ELUT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELUT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELUT stock methods without spending real money on the virtual paper trading platform.